Deferasirox (Jadenu)
Jump to navigation
Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
General information
Class/mechanism: Iron chelating agent; selective for the ferric form of iron: iron(III), Fe3+.[1][2][3]
Route: PO (tablet); the PO powder form of this medication is Deferasirox (Exjade)
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Iron overload, secondary hemochromatosis
Patient drug information
- Patient counseling information can be found in the Deferasirox (Jadenu) package insert[1]
- Deferasirox (Exjade) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 2015-03-30: Accelerated FDA approval for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older.
- 2015-03-30: Accelerated FDA approval for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L.
Also known as
- Brand name: Jadenu